Core Viewpoint - Kangzheng Pharmaceutical (00867) has signed an exclusive distribution agreement for Lidoderm® (lidocaine gel patch) with Teikoku Pharma USA, Inc., granting the company exclusive rights to distribute the product in mainland China for a period of ten years, with potential for renewal [1] Group 1: Product and Market Overview - Lidoderm is a topical patch that blocks voltage-gated sodium channels, reducing pain for patients with postherpetic neuralgia (PHN) [2] - The product was approved by the FDA in 1999 and has shown significant efficacy, with approximately 25% to 33% of patients experiencing at least 50% pain relief in clinical studies lasting 4 to 12 weeks [2] - PHN is a common complication of shingles, with a prevalence that increases with age; about 30% to 50% of patients may experience pain lasting over one year, and in China, it is estimated that there are around 4 million PHN patients [3] Group 2: Company and Partner Profile - Teikoku Pharma USA, Inc. is a subsidiary of Teikoku Seiyaku Co., Ltd., which has a long history in developing innovative products in pain management and dermatology [4] - Teikoku Seiyaku is one of the largest manufacturers of hydrogel patches and has a diverse portfolio of over 200 prescription and over-the-counter products distributed in more than 50 countries [4] Group 3: Strategic Implications for Kangzheng Pharmaceutical - The introduction of Lidoderm enhances Kangzheng's product portfolio and is expected to create synergies with existing products, leveraging expert resources and marketing channels [5] - The company aims to expand its presence in the outpatient market and develop a comprehensive commercial ecosystem that integrates online and offline channels [5] - The board believes that the terms of the agreement are fair and reasonable, aligning with the overall interests of the company and its shareholders [5]

Group 1 - 康哲药业 has signed an exclusive distribution agreement with Teikoku Pharma USA, Inc. for the Lidoderm product, granting the company exclusive rights in mainland China for ten years starting from the first commercial sale [1] - Lidoderm is a lidocaine patch approved by the FDA in 1999 for treating postherpetic neuralgia (PHN), with clinical studies showing about 25% to 33% of patients experiencing at least 50% pain relief within 4 to 12 weeks [2] - The prevalence of PHN is significant, with estimates suggesting that approximately 4 million patients in China may be affected, particularly among older populations [3] Group 2 - Teikoku Pharma USA, Inc. is a subsidiary of Teikoku Seiyaku Co., Ltd., which has a long history in developing innovative products for pain management and other therapeutic areas [4] - The introduction of Lidoderm enhances 康哲药业's product portfolio and is expected to synergize with existing products, expanding market reach and driving growth [5] - The company aims to leverage new retail and multi-channel marketing strategies to create a comprehensive commercial ecosystem, enhancing both hospital and outpatient market penetration [5]

Group 1 - The company signed an exclusive distribution agreement for Lidoderm® with Teikoku Pharma USA, Inc., granting exclusive rights in mainland China for ten years starting from the first commercial sale [1] - Lidoderm® is a lidocaine patch approved by the FDA in 1999 for treating postherpetic neuralgia (PHN), with clinical studies showing about 25% to 33% of patients experiencing at least 50% pain relief within 4 to 12 weeks [2] - The product is recognized in clinical guidelines for its effectiveness and safety in treating PHN and other neuropathic pain conditions, such as diabetic peripheral neuropathic pain [2][3] Group 2 - PHN is defined as pain persisting for one month or more after the healing of herpes zoster rash, with a significant prevalence among older adults, particularly those aged 60 and above [3] - The company aims to enhance its product portfolio with Lidoderm®, leveraging its brand advantages and existing marketing channels to create synergies and expand into new retail models [5] - The collaboration is expected to positively impact the company's operational performance and align with the interests of its shareholders [5] Group 3 - Teikoku Pharma USA, Inc. is a subsidiary of Teikoku Seiyaku Co., Ltd., which has a long history in developing innovative products in pain management and dermatology, producing over 200 prescription and over-the-counter products [4] - The demand for pain management solutions, particularly for PHN, is significant, and topical patches are well-recognized in the Chinese market for their direct and convenient application [4]